BioCryst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-8.78	-88.88	-226.54	-247.12	-184.06	-182.81
Depreciation & Amortization	3.07	3.01	2.87	2.25	0.89	0.75
Loss (Gain) From Sale of Assets	-0.55	-	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	1.55	-	-	-
Loss (Gain) From Sale of Investments	-6	-11.47	-10.26	-1.78	-0	0.12
Stock-Based Compensation	82.61	65.41	55.62	44.7	34.64	14.79
Other Operating Activities	52.3	67.19	114.03	99.03	-1.75	5.17
Change in Accounts Receivable	-28.61	-22.7	-6.1	-21.47	-20.82	13.9
Change in Inventory	-3.29	-4.16	-1.45	-12.42	-8.77	-7.04
Change in Accounts Payable	-34.31	-62.38	-16.81	-22.36	39.41	17.36
Change in Unearned Revenue	-	-	-1.23	-0.11	1.28	-1.97
Change in Other Net Operating Assets	-6.25	1.96	-6.82	-2.58	-2.99	4.63
Operating Cash Flow	50.2	-52.02	-95.14	-161.85	-142.16	-135.11
Capital Expenditures	-2.34	-1.12	-2.17	-1.35	-2.39	-0.51
Sale of Property, Plant & Equipment	0.55	-	-	-	-	-
Investment in Securities	89.38	53.72	-129.33	-126.89	18.19	-6.34
Investing Cash Flow	87.59	52.59	-131.5	-128.24	15.8	-6.86
Long-Term Debt Issued	-	-	300	73.07	293.87	242.47
Long-Term Debt Repaid	-	-1.7	-241.62	-	-	-52.42
Net Debt Issued (Repaid)	-137.98	-1.7	58.38	73.07	293.87	190.05
Issuance of Common Stock	7.91	3.48	8.68	14.96	65.79	95.73
Other Financing Activities	-5.93	-7.54	-34.58	-	-	14.82
Financing Cash Flow	-135.99	-5.76	32.49	88.03	359.67	300.59
Foreign Exchange Rate Adjustments	0.04	-0.94	0.36	0.57	0.07	-
Net Cash Flow	-13.01	-6.12	-193.79	-201.5	233.39	158.63
Free Cash Flow	47.86	-53.14	-97.31	-163.2	-144.54	-135.62
Free Cash Flow Margin	7.98%	-11.79%	-29.36%	-60.26%	-91.97%	-761.41%
Free Cash Flow Per Share	0.23	-0.26	-0.51	-0.88	-0.81	-0.81
Cash Interest Paid	32.93	30.38	22.14	-	0.9	-
Cash Income Tax Paid	2.6	1.6	1.43	3.54	0.12	-
Levered Free Cash Flow	63.34	11.95	-67.23	-141.51	-122.67	-73.33
Unlevered Free Cash Flow	119.08	73.52	0.42	-79.58	-85.61	-64.27
Change in Working Capital	-72.46	-87.28	-32.4	-58.95	8.12	26.88

Source: S&P Global Market Intelligence. Standard template. Financial Sources.